Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04899947 · ClinicalTrials.gov registry record
Child and Adolescent Registry for Participants With Narcolepsy
A clinical trial of Narcolepsy, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT04899947: Recruiting study of Narcolepsy, sponsored by Jazz Pharmaceuticals.
NCT04899947 is a study of Narcolepsy that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 500 participants, above the 339-participant average among 12 other Narcolepsy trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04899947, a study of Narcolepsy, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com. The Online Patient Enrollment System, CATNAP website, can also be found in the references section.
Conditions Studied
Study Locations (20)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- University Hospitals Cleveland Medical Centre (UHCMC) - Cleveland
- Nationwide Children's Hospital - Columbus
Arizona
- Phoenix Children's Hospital - Phoenix
- University of Arizona - Tucson
Arkansas
- University of Arkansas - Fayetteville
- Arkansas Children's Research Institute - Little Rock
California
- Stanford University - Redwood City
- University of California San Diego - San Diego
District of Columbia
- Children's National Medical Center - Washington D.C.
- Children's Research Institute - Washington D.C.
Michigan
- Trinity Health-Michigan - Grand Rapids
- Mayo Clinic - Rochester
Missouri
- St. Luke's Hospital - Chesterfield
- Children's Mercy Hospital - Kansas City
Florida
- University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-10-10 |
| Est. Completion | 2024-10-01 |
What NCT04899947 shows while recruiting
NCT04899947 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 339-participant average among 12 other Narcolepsy trials with a reported enrollment target (47% higher).
The record links to 1 condition, with Narcolepsy appearing as the primary indexed condition, and to 0 interventions.
NCT04899947 names 20 study sites across 12 states, led by Ohio, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04899947 about?
NCT04899947 is a clinical study titled "Child and Adolescent Registry for Participants With Narcolepsy". CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the ...
What is the current status of trial NCT04899947?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2020-10-10. Estimated completion is 2024-10-01.
What conditions does trial NCT04899947 study?
This clinical trial studies the following conditions: Narcolepsy.
Who is sponsoring clinical trial NCT04899947?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04899947 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Narcolepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04899947's enrollment target sits among peer trials
500 3rd of 12 higher than 10 of 12 other Narcolepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Narcolepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SUNOSI® (Solriamfetol) Pregnancy Registry
RECRUITING
-
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
RECRUITING · Phase 1
-
WAKIX® (Pitolisant) Pregnancy Registry
RECRUITING
-
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
COMPLETED · Phase 2
-
Narcolepsy Nightmare Study
COMPLETED · NA
-
Psychosocial Adjunctive Treatment for Hypersomnia (PATH)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI